$GILD News Seven health stocks with buy signal
Post# of 94125
![Avatar](/images/ProfileImages/410421673_9050_Stock_Tracker.jpg)
Seven health stocks with buy signals 10:21 a.m. Dec. 11, 2014 - The Trading Deck
Newscast: Oil called the tune on Wall St. 4:21 p.m. Dec. 10, 2014 - MarketWatch
Cypress, Spansion shares rally on merger plan 5:36 p.m. Dec. 1, 2014 - MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug 7:49 a.m. Dec. 1, 2014 - Angela Chen
10 stocks that may revisit their highs as the year ends 10:30 a.m. Nov. 24, 2014 - Philip van Doorn
Are consumers getting gouged on health care? 9:35 a.m. Nov. 22, 2014 - Russ Britt
Gilead Sciences shares slide 1.7% 9:35 a.m. Nov. 19, 2014 - Sue Chang
The double-edged sword of growth-stock speculation 2:29 p.m. Nov. 14, 2014 - The Trading Deck
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers 9:31 a.m. Nov. 10, 2014 - Sue Chang
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
What Makes Apple So Special? 3:29 p.m. Dec. 13, 2014 - Seeking Alpha
The Collapse In Oil Prices Rocks The Markets 2:45 p.m. Dec. 13, 2014 - Seeking Alpha
Seeking Alpha's Biotech Weekly: Spark Flies For Pfizer, Sovaldi V. Septa, And More 3:29 p.m. Dec. 12, 2014 - Seeking Alpha
Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis 3:27 p.m. Dec. 12, 2014 - Seeking Alpha
Harvoni + Sovaldi scripts in line to hit consensus 11:51 a.m. Dec. 12, 2014 - Seeking Alpha
Gilead Is Growing Fast And Its Stock Is Cheap 11:13 a.m. Dec. 12, 2014 - Barrons.com
These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market 10:44 a.m. Dec. 12, 2014 - benzinga.com
Act Fast to Trade These Gilead Sciences (GILD) Options 12:30 a.m. Dec. 12, 2014 - InvestorPlace.com
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily
6 Strong Analyst Recommendations That You Should Know 10:49 a.m. Dec. 11, 2014 - benzinga.com
Tell Me How You Really Feel: A Look At The Market Through Analyst Consensus Recommendations 8:02 a.m. Dec. 11, 2014 - Seeking Alpha
3 Ways to Play the Bounce in Biotech Stocks 7:35 a.m. Dec. 11, 2014 - InvestorPlace.com
Philadelphia transit agency sues Gilead over Sovaldi pricing 4:10 p.m. Dec. 10, 2014 - Seeking Alpha
Gilead Faces Suit Over Drug’s Price 4:02 p.m. Dec. 10, 2014 - The Wall Street Journal Interactive Edition
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Gilead Sciences: First Oncology Drug Strengthens War Chest 12:45 p.m. Dec. 9, 2014 - Seeking Alpha
The Contagion From The Imploding Oil Market Spreads 10:51 a.m. Dec. 9, 2014 - Seeking Alpha
UPDATE: Morgan Stanley Raises PT on Gilead Sciences Following AlphaWise Survey 10:10 a.m. Dec. 9, 2014 - benzinga.com
T Rowe Price's Top Stakes for the Third Quarter 9:16 a.m. Dec. 9, 2014 - GuruFocus.com
Critical Alerts For Abercrombie & Fitch, Whole Foods Market, Gilead Sciences, JC Penney and Activision Blizzard Released By InvestorsObserver 9:31 a.m. Dec. 10, 2014 - PR Newswire - PRF
Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi 6:39 p.m. Dec. 9, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:43 p.m. Dec. 9, 2014 - PR Newswire - PRF
Biogen Idec and Gilead Sciences Join the National Pharmaceutical Council 9:15 a.m. Dec. 9, 2014 - PR Newswire - PRF
Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 10:00 a.m. Dec. 8, 2014 - BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM 8:45 a.m. Dec. 8, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power 8:45 a.m. Dec. 4, 2014 - PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries 7:00 a.m. Dec. 1, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry 8:45 a.m. Nov. 26, 2014 - PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver 9:31 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power 8:45 a.m. Nov. 20, 2014 - PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead 5:11 p.m. Nov. 19, 2014 - Marketwired
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 10:07 a.m. Nov. 18, 2014 - BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba 8:45 a.m. Nov. 18, 2014 - PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com 8:45 a.m. Nov. 14, 2014 - PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes 5:59 p.m. Nov. 12, 2014 - BusinessWire - BZX
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper 8:45 a.m. Nov. 12, 2014 - PR Newswire - PRF
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)